COVID Applies the Brakes: Q420/FY20 Spinal Cord Stimulation Market Recap

While US SCS revenues were almost back to pre-COVID levels in Q320, rising COVID case rates put the brakes on procedure growth by the end of Q420 and the US and WW SCS markets ended down -15%+ in FY20 compared to FY19.

Although spinal cord stimulation (SCS) revenues were almost back to pre-COVID levels in Q320, by the end of Q420, rising COVID case rates in certain geographies put the brakes on procedure growth, resulting in a low-single-digit (LSD) decrease in YoY revenues in both the US and WW in Q420. For the full year (FY), US SCS were down -15.1%, with revenues, according to SmartTRAK SCS Financial Dashboard, totaling ...

Among the many topics covered in the comprehensive Q420/FY20 Spinal Cord Stimulation Market Recap * are:

• Complete Market Overview
• Companies' Revenue and Market Share
• Abbott Ends Year as No. 1
• Boston Scientific: WaveWriter Alpha Poised for Growth
• Medtronic: Gaining Momentum in Pain Stim
• Nevro Gains Share in 2020
• Other Players: Stimwave’s Strategic Shift
• Recent Clinical/Regulatory News and Highlights
  

In the US, Abbott* (ABT) remained the US SCS market leader in Q420, followed by Boston Scientific*, Medtronic*, Nevro* and Other. On a WW basis, ABT held the No. 1 share position in Q420, followed by MDT and ...

Read the entire Q420/FY20 Spinal Cord Stimulation Market Recap including news, data, charts, company revenues, shares and analysis*

*The entire article and the links can only be viewed by SmartTRAK subscribers to this module. For more information on how to receive a demo and subscribe, please click here.